The National Comprehensive Cancer Network (NCCN) released updated Genetic/Familial High-Risk Assessment: Colorectal, Endometrial, Gastric Cancer guidelines on June 13th, 2025 (Version 1.2025). Included in these new guidelines are updates to the surgical options for Lynch carriers and updates to the PMS2 content as outlined below:
- Removed cancer risks for ovarian, renal pelvis and ureter, bladder, gastric, small bowel, pancreas, biliary tract, prostate, breast (female), brain, and skin.
- Replaced with: While other LS-associated cancers have been observed in individuals with PMS2 LS, it is unclear whether PMS2 LS carriers have increased (for these cancers, data are insufficient to provide cancer risk estimates or cancer surveillance/risk reduction recommendations)
- Surveillance regimens for cancers other than CRCs or ECs among PMS2 LS carriers should be individualized based on personal and family cancer history, and clinical judgment.
To read more, check out the full guidelines by creating a FREE account at:
https://www.nccn.org/professionals/physician_gls/pdf/genetics_ceg.pdf